Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort

Katri Korpela, Anne Salonen, Harri Saxen, Anne Nikkonen, Ville Peltola, Tytti Jaakkola, Willem de Vos, Kaija Leena Kolho*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: The effects of antibiotics on infant gut microbiota are unclear. We hypothesized that the use of common antibiotics results in long-term aberration in gut microbiota. METHODS: Antibiotic-naive infants were prospectively recruited when hospitalized because of a respiratory syncytial virus infection. Composition of fecal microbiota was compared between those receiving antibiotics during follow-up (prescribed at clinicians’ discretion because of complications such as otitis media) and those with no antibiotic exposure. Fecal sampling started on day 1, then continued at 2-day intervals during the hospital stay, and at 1, 3 and 6 months at home. RESULTS: One hundred and sixty-three fecal samples from 40 patients (median age 2.3 months at baseline; 22 exposed to antibiotics) were available for microbiota analyses. A single course of amoxicillin or macrolide resulted in aberration of infant microbiota characterized by variation in the abundance of bifidobacteria, enterobacteria and clostridia, lasting for several months. Recovery from the antibiotics was associated with an increase in clostridia. Occasionally, antibiotic use resulted in microbiota profiles associated with inflammatory conditions. CONCLUSIONS: Antibiotic use in infants modifies especially bifidobacterial levels. Further studies are warranted whether administration of bifidobacteria will provide health benefits by normalizing the microbiota in infants receiving antibiotics.

Original languageEnglish
JournalPediatric Research
DOIs
Publication statusPublished - 18 Jan 2020

Fingerprint

Anti-Bacterial Agents
Microbiota
Bifidobacterium
Clostridium
Gastrointestinal Microbiome
Respiratory Syncytial Virus Infections
Amoxicillin
Macrolides
Otitis Media
Insurance Benefits
Enterobacteriaceae
Length of Stay

Cite this

Korpela, Katri ; Salonen, Anne ; Saxen, Harri ; Nikkonen, Anne ; Peltola, Ville ; Jaakkola, Tytti ; de Vos, Willem ; Kolho, Kaija Leena. / Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort. In: Pediatric Research. 2020.
@article{ff2f18045c1b43b1bb8dcc6eee008f45,
title = "Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort",
abstract = "BACKGROUND: The effects of antibiotics on infant gut microbiota are unclear. We hypothesized that the use of common antibiotics results in long-term aberration in gut microbiota. METHODS: Antibiotic-naive infants were prospectively recruited when hospitalized because of a respiratory syncytial virus infection. Composition of fecal microbiota was compared between those receiving antibiotics during follow-up (prescribed at clinicians’ discretion because of complications such as otitis media) and those with no antibiotic exposure. Fecal sampling started on day 1, then continued at 2-day intervals during the hospital stay, and at 1, 3 and 6 months at home. RESULTS: One hundred and sixty-three fecal samples from 40 patients (median age 2.3 months at baseline; 22 exposed to antibiotics) were available for microbiota analyses. A single course of amoxicillin or macrolide resulted in aberration of infant microbiota characterized by variation in the abundance of bifidobacteria, enterobacteria and clostridia, lasting for several months. Recovery from the antibiotics was associated with an increase in clostridia. Occasionally, antibiotic use resulted in microbiota profiles associated with inflammatory conditions. CONCLUSIONS: Antibiotic use in infants modifies especially bifidobacterial levels. Further studies are warranted whether administration of bifidobacteria will provide health benefits by normalizing the microbiota in infants receiving antibiotics.",
author = "Katri Korpela and Anne Salonen and Harri Saxen and Anne Nikkonen and Ville Peltola and Tytti Jaakkola and {de Vos}, Willem and Kolho, {Kaija Leena}",
year = "2020",
month = "1",
day = "18",
doi = "10.1038/s41390-020-0761-5",
language = "English",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Palgrave Macmillan",

}

Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort. / Korpela, Katri; Salonen, Anne; Saxen, Harri; Nikkonen, Anne; Peltola, Ville; Jaakkola, Tytti; de Vos, Willem; Kolho, Kaija Leena.

In: Pediatric Research, 18.01.2020.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Antibiotics in early life associate with specific gut microbiota signatures in a prospective longitudinal infant cohort

AU - Korpela, Katri

AU - Salonen, Anne

AU - Saxen, Harri

AU - Nikkonen, Anne

AU - Peltola, Ville

AU - Jaakkola, Tytti

AU - de Vos, Willem

AU - Kolho, Kaija Leena

PY - 2020/1/18

Y1 - 2020/1/18

N2 - BACKGROUND: The effects of antibiotics on infant gut microbiota are unclear. We hypothesized that the use of common antibiotics results in long-term aberration in gut microbiota. METHODS: Antibiotic-naive infants were prospectively recruited when hospitalized because of a respiratory syncytial virus infection. Composition of fecal microbiota was compared between those receiving antibiotics during follow-up (prescribed at clinicians’ discretion because of complications such as otitis media) and those with no antibiotic exposure. Fecal sampling started on day 1, then continued at 2-day intervals during the hospital stay, and at 1, 3 and 6 months at home. RESULTS: One hundred and sixty-three fecal samples from 40 patients (median age 2.3 months at baseline; 22 exposed to antibiotics) were available for microbiota analyses. A single course of amoxicillin or macrolide resulted in aberration of infant microbiota characterized by variation in the abundance of bifidobacteria, enterobacteria and clostridia, lasting for several months. Recovery from the antibiotics was associated with an increase in clostridia. Occasionally, antibiotic use resulted in microbiota profiles associated with inflammatory conditions. CONCLUSIONS: Antibiotic use in infants modifies especially bifidobacterial levels. Further studies are warranted whether administration of bifidobacteria will provide health benefits by normalizing the microbiota in infants receiving antibiotics.

AB - BACKGROUND: The effects of antibiotics on infant gut microbiota are unclear. We hypothesized that the use of common antibiotics results in long-term aberration in gut microbiota. METHODS: Antibiotic-naive infants were prospectively recruited when hospitalized because of a respiratory syncytial virus infection. Composition of fecal microbiota was compared between those receiving antibiotics during follow-up (prescribed at clinicians’ discretion because of complications such as otitis media) and those with no antibiotic exposure. Fecal sampling started on day 1, then continued at 2-day intervals during the hospital stay, and at 1, 3 and 6 months at home. RESULTS: One hundred and sixty-three fecal samples from 40 patients (median age 2.3 months at baseline; 22 exposed to antibiotics) were available for microbiota analyses. A single course of amoxicillin or macrolide resulted in aberration of infant microbiota characterized by variation in the abundance of bifidobacteria, enterobacteria and clostridia, lasting for several months. Recovery from the antibiotics was associated with an increase in clostridia. Occasionally, antibiotic use resulted in microbiota profiles associated with inflammatory conditions. CONCLUSIONS: Antibiotic use in infants modifies especially bifidobacterial levels. Further studies are warranted whether administration of bifidobacteria will provide health benefits by normalizing the microbiota in infants receiving antibiotics.

U2 - 10.1038/s41390-020-0761-5

DO - 10.1038/s41390-020-0761-5

M3 - Article

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

ER -